A Two-part, Single- and Two Arm Randomized, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy (in Part 2 Only) of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies
Latest Information Update: 26 Jul 2023
At a glance
- Drugs Mocravimod (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 15 Jun 2023 Results exploring relapse and survival outcomes for the subgroup of AML pts included in this study in comparison to a control group of AML pts undergoing allo-HCT who did not receive MOC treatment during the same time at one study site, presented at the 28th Congress of the European Haematology Association
- 01 Jan 2023 Results published in the Transplantation and Cellular Therapy
- 17 Jun 2022 Results presented at the 27th Congress of the European Haematology Association